1-6 of 6
Authors: Anthony T. Podany
Journal Article
Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention Free
Clinical Infectious Diseases, Volume 79, Issue 4, 15 October 2024, Pages 983–989, https://doi.org/10.1093/cid/ciae183
Published: 03 April 2024
Journal Article
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349) Get access
Clinical Infectious Diseases, Volume 76, Issue 3, 1 February 2023, Pages e580–e589, https://doi.org/10.1093/cid/ciac707
Published: 30 August 2022
Journal Article
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine Free
Clinical Infectious Diseases, Volume 75, Issue 4, 15 August 2022, Pages 560–566, https://doi.org/10.1093/cid/ciab1037
Published: 16 December 2021
Journal Article
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus–Tuberculosis Coinfection Free
Clinical Infectious Diseases, Volume 73, Issue 4, 15 August 2021, Pages 706–715, https://doi.org/10.1093/cid/ciab097
Published: 09 February 2021
Journal Article
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention Free
Clinical Infectious Diseases, Volume 61, Issue 8, 15 October 2015, Pages 1322–1327, https://doi.org/10.1093/cid/civ464
Published: 16 June 2015
Journal Article
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment Get access
Clinical Infectious Diseases, Volume 61, Issue 4, 15 August 2015, Pages 633–639, https://doi.org/10.1093/cid/civ346
Published: 28 April 2015
